---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-007055"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T14:27:34.001313+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotechnology reports Q1 2023 net loss $4.1M; positive THIO-101 Phase 2 data and $5.75M offering

## Summary
- Cash $7.6M at March 31, 2023; net loss $4.1M for Q1 2023 vs $3.9M for Q1 2022.
- R&D expenses $2.2M, G&A expenses $2.0M for the quarter, both modestly higher YoY.
- Completed Part A safety lead-in of THIO-101 Phase 2 trial; first two patients alive ~10 and 9 months post treatment.
- THIO showed complete and durable responses in hepatocellular carcinoma in vivo models, potentiated with checkpoint inhibitor.
- Raised $5.75M gross from public offering of 2,555,500 shares at $2.25 per share.

## SEC filing metadata
- accession: 0001564590-23-007055
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/0001564590-23-007055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/maia-8k_20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-007055
- JSON: https://secwatch.observer/filing/0001564590-23-007055.json
- Plain text: https://secwatch.observer/filing/0001564590-23-007055.txt

## Key facts
- Earnings Releases
  MAIA Biotechnology, Inc. reported first quarter ended March 31, 2023 results: net income approximately $4.1 million.
  - Period: first quarter ended March 31, 2023
  - Net income: approximately $4.1 million
  - Result: reported results
  source text: Net loss was approximately $4.1 million for the quarter ended March 31, 2023, as compared to net loss of approximately $3.9 million for the quarter ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1878313/000156459023007055/0001564590-23-007055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.